ARCT logo

ARCTURUS THERAPEUTICS HOLDIN

ARCTNASDAQ
๐Ÿ† #3422 by market capUS Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track ARCT
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$215M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-76.0%
Declining
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
704.6%
Strong
โš–๏ธP/S Ratio
7.3x
Fair
Otter Score
โ€”
Insufficient data
No chart data available for ARCT.

Trading Snapshot

Day Range
โ€”
52-Week Range
$5.50 โ€“ $17.96
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
28.4M
Next Earnings
โ€”

Fundamentals Snapshot

Annual Revenue
$67M
Last Q Revenue
$18M
P/E Ratio
โ€”
P/S Ratio
7.3x
EPS (TTM)
$-3.31
Dividend Yield
โ€”
ARCT logo

ARCTURUS THERAPEUTICS HOLDIN

ARCT
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About ARCTURUS THERAPEUTICS HOLDIN

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.